The purpose of this study is to test the potential of the rapid-acting anti-depressant
ketamine to decrease suicidality in Borderline Personality Disorder (BPD).
The rate of completed suicide in BPD is similar to that of depression or schizophrenia. There
is currently no specific medication treatment for BPD.
Ketamine is an FDA-approved anesthetic agent that has been shown to rapidly decrease
suicidality and improve mood in people with Major Depressive Disorder (MDD). Though symptoms
overlap, effective treatments for MDD and BPD differ. This clinical trial tests if ketamine
also decreases suicidality and improves mood in BPD.
This trial will also measure several other outcomes after ketamine versus placebo in BPD:
adverse events, BPD symptoms, pain, social cognition, and neuroplasticity.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Collaborators:
American Foundation for Suicide Prevention Nathan Kline Institute for Psychiatric Research